Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.70 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.70 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.68 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | HINT1 | P49773 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 4/20 | 0.58 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.57 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720437 | 1.00 | TAS1R3 (0.70) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL25391360 | 1.00 | TAS1R3 (0.70) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL14576179 | 1.00 | TAS1R3 (0.70) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL26067681 | 1.00 | TAS1R3 (0.70) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL26067564 | 0.94 | NT5E (0.67) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL26067581 | 0.94 | NT5E (0.67) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL21715304 | 0.93 | TGM2 (0.69) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL21715305 | 0.93 | TGM2 (0.69) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL26067682 | 0.93 | TGM2 (0.69) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 | |
| SCHEMBL843561 | 0.93 | TAS1R3 (0.68) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745239-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | Rigerna Therapeutics Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2025031301-A1 | FTO INHIBITOR COMPOSITION AND USE THEREOF | 苏州炫景生物科技有限公司 | 2025-02-13 | — | — | WO | claimed |
| WO-2025026228-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | 苏州炫景生物科技有限公司 | 2025-02-06 | — | — | WO | claimed |
| EP-4745239-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | Rigerna Therapeutics Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025031301-A1 | FTO INHIBITOR COMPOSITION AND USE THEREOF | 苏州炫景生物科技有限公司 | 2025-02-13 | — | — | WO | disclosed |
| WO-2025026228-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | 苏州炫景生物科技有限公司 | 2025-02-06 | — | — | WO | disclosed |
| US-20240327834-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-11884919-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3954225-B1 | INITIATING CAPPED OLIGONUCLEOTIDE PRIMERS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20220243199-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | BANK OF AMERICA, N.A. | 2022-08-04 | — | — | US | disclosed |
| US-11149273-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20070197460-A1 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | ALNYLAM EUROPE AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | MEDTRONIC, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070044161-A1 | RNAi modulation of the Rho-A gene in research models | YALE UNIVERSITY | 2007-02-22 | — | — | US | disclosed |
| US-20070042984-A1 | RNAi modulation of the Rho-A gene and uses thereof | BANK OF AMERICA, N.A. | 2007-02-22 | — | — | US | disclosed |
| US-20060217324-A1 | RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof | ALNYLAM PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060105976-A1 | RNAi modulation of ApoB and uses thereof | BANK OF AMERICA, N.A. | 2006-05-18 | — | — | US | disclosed |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | BANK OF AMERICA, N.A. | 2006-05-04 | — | — | US | disclosed |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | ALNYLAM PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217324-A1 | RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof | RTN4, RTN3, GAP43 | TAS1R3 1780/4885TAS1R1 2525/4885NT5E 197/4885 |
| US-11149273-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene | SAAL1, APOB, HNRNPAB | TAS1R3 3427/4885TAS1R1 3230/4885NT5E 1593/4885 |
| US-20060105976-A1 | RNAi modulation of ApoB and uses thereof | APOB, LDLR, APOL1 | TAS1R3 3719/4885TAS1R1 4249/4885NT5E 2183/4885 |
| US-20070197460-A1 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | SNRPE, EIF2AK2, AGO2 | TAS1R3 4367/4885TAS1R1 4567/4885NT5E 321/4885 |
| US-11884919-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene | SAAL1, APOB, SCARB1 | TAS1R3 3148/4885TAS1R1 2989/4885NT5E 1309/4885 |
| US-20240327834-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | SAAL1, APOB, SCARB1 | TAS1R3 3148/4885TAS1R1 2989/4885NT5E 1309/4885 |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | BAX, BCL2, API5 | TAS1R3 4174/4885TAS1R1 4209/4885NT5E 1482/4885 |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | RNASE1, RNASEH1, RNASEL | TAS1R3 3448/4885TAS1R1 3383/4885NT5E 465/4885 |
| US-20070044161-A1 | RNAi modulation of the Rho-A gene in research models | RHOA, RHOC, ARHGDIA | TAS1R3 4478/4885TAS1R1 4746/4885NT5E 1581/4885 |
| US-20070099860-A1 | Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington's disease | HTT, HYPK, DHX36 | TAS1R3 2938/4885TAS1R1 3181/4885NT5E 1330/4885 |
| US-20220243199-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | SAAL1, APOB, HNRNPAB | TAS1R3 3427/4885TAS1R1 3230/4885NT5E 1593/4885 |
| US-20070042984-A1 | RNAi modulation of the Rho-A gene and uses thereof | RHOA, ARHGDIA, RHOC | TAS1R3 4658/4885TAS1R1 4827/4885NT5E 1484/4885 |
| US-20070105806-A1 | Compositions and methods for inhibiting expression of Nav1.8 gene | SCN8A, SCN7A, SCN5A | TAS1R3 1696/4885TAS1R1 1811/4885NT5E 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.